Immunological* / economics

Glofitamab Treatment for DLBCL Shows Cost Savings Over Epcoritamab in US Healthcare

Aug 8, 2025

An economic model reveals glofitamab offers DLBCL patient cost savings versus epcoritamab, despite higher adverse event and treatment administration costs.

Recent Posts

Utah workers continue amid shutdown, unpaid
Federal workforce cuts and deferred resignations are causing stress for many, as the government shutdown could mean unpaid work.
Impact of 2025 Government Shutdown on Medicare and Medicaid Policies
Congress' inability to pass a federal fiscal year 2026 continuing resolution has resulted in a federal government shutdown, affecting healthcare policies and payments.
Federal Government Shutdown as Congressional Parties Escalate Funding Standoff
Government shutdown approaches as Republicans and Democrats clash over federal funding, with health care at the center of the dispute.
Friendship at Risk: Opposing Parenting Styles Impact
Understanding Different Parenting Styles and Friendships When it comes to friendships, we often look for commonalities in interests, humor, trust, and enjoyment of each other’s… Read more: Friendship at Risk: Opposing Parenting Styles Impact
Trump’s Bill Act Leaves Major Ports Unaffected So Far
Trump's One Big Beautiful Bill Act alters funding for environmental programs, potentially impacting port equipment funding under DERA grants.